

A Predictive Autoantibody Signature in Multiple Sclerosis

Colin R. Zamecnik^{a*}, Gavin M. Sowa^{b*}, Ahmed Abdelhak^a, Ravi Dandekar^a, Rebecca D. Bair^a, Kristen J. Wade^a, Christopher M. Bartley^c, Asritha Tubati^a, Refujia Gomez^a, Camille Fouassier^a, Chloe Gerungan^a, Jessica Alexander^a, Anne E. Wapniarski^a, Rita P. Loudermilk^a, Erica L. Eggers^a, Kelsey C. Zorn^d, Kirtana Ananth^a, Nora Jabassini^a, Sabrina A. Mann^d, University of California, Nicholas R. Ragan^a, Adam Santaniello^a, Roland G. Henry^a, Sergio E. Baranzini^a, Scott S. Zamvil^a, Riley M. Bove^a, Chu-Yueh Guo^a, Jeffrey M. Gelfand^a, Richard Cuneo^a, H.-Christian von Büdingen^a, Jorge R. Oksenberg^a, Bruce AC Cree^a, Jill A. Hollenbach^{a,e}, Ari J. Green^a, Stephen L. Hauser^a, Mitchell T. Wallin^f, Joseph L. DeRisi^{d,g}, Michael R. Wilson^{a,**}

^a UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA, USA

^b Department of Medicine, McGaw Medical Center of Northwestern University, Chicago, IL, USA

^c UCSF Weill Institute for Neurosciences, Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, CA, USA

^d Department of Biochemistry and Biophysics, University of California, San Francisco, CA, USA

^e Department of Epidemiology and Biostatistics, University of California, San Francisco, CA USA

^f Veterans Affairs, Multiple Sclerosis Center of Excellence, Washington, DC and University of Maryland School of Medicine, Baltimore, MD, USA

^g Chan Zuckerberg Biohub, San Francisco, CA, USA

*equal contributions

**Correspondence should be addressed to Prof. Michael Wilson

Email: Michael.Wilson@ucsf.edu

Table 1 - DoDSR cohort demographics.

	MS Cases	Healthy Controls	Overall
	(N=250)	(N=250)	(N=500)
Gender			
Female	84 (33.6%)	84 (33.6%)	168 (33.6%)
Male	166 (66.4%)	166 (66.4%)	332 (66.4%)
Race and Ethnicity			
White	159 (63.6%)	159 (63.6%)	318 (63.6%)
Black	86 (34.4%)	86 (34.4%)	172 (34.4%)
Hispanic Ethnicity	5 (2.0%)	5 (2.0%)	10 (2.0%)
Birth year			
Mean (SD)	1970 (8.0)	1970 (8.0)	1970 (8.0)
Time between samples (years)			
Mean (SD)	6.18 (3.3)	6.07 (3.4)	6.12 (3.3)
MS Subtype			
Relapsing Remitting	192 (76.8%)	0 (0%)	192 (38.4%)
Secondary Progressive	43 (17.2%)	0 (0%)	43 (8.6%)
Primary Progressive	14 (5.6%)	0 (0%)	14 (2.8%)
Progressive Relapsing	1 (0.4%)	0 (0%)	1 (0.2%)

Post Onset Serum Sample Collection (years*)			
Mean (SD)	1.2 (0.4)	NA	1.2 (0.4)
*Time in years from first symptom onset to serum collection			

Table 2 - ORIGINS cohort demographics.

ORIGINS cohort		
	MS (n=103)	OND (n=23)
Sex		
Female, n (%)	67 (65.0%)	14 (60.9%)
Male, n (%)	36 (35.0%)	9 (39.1%)
Age, yrs (mean \pm SD)	34.1 \pm 7.4	39.9 \pm 13.4
Race		
White, n (%)	74 (71.8%)	15 (65.2%)
Black, n (%)	4 (3.9%)	2 (8.7%)
Asian, n (%)	9 (8.7%)	1 (4.3%)
Ethnicity		
Latino, n (%)	8 (17.5%)	3 (13.0%)
Not Latino, n (%)	95 (82.5%)	20 (87%)
EDSS (median [IQR] {Range})	2 [1.5, 2.9] {0-6.5}	
Disease duration, months (median [IQR] {Range})	1 [0, 1] {0-19}	

Table 3 - MS_{IC} demographic analysis.

	MS _{IC}	MS _{no-IC}	P-value
	(N=27)	(N=223)	
Race and Ethnicity			
White	21 (77.8%)	138 (61.9%)	0.164
Black	5 (18.5%)	81 (36.3%)	
Hispanic Ethnicity	1 (3.7%)	4 (1.8%)	
Sex			
Female	9 (33.3%)	75 (33.6%)	1.0
Male	18 (66.7%)	148 (66.4%)	
Age at First Symptom Onset (years)			
Mean (SD)	28.6 (7.0)	29.7 (6.8)	0.5
Median [Min, Max]	29.0 [18.0, 42.0]	29.0 [18.0, 49.0]	
MS Subtype			
Relapsing Remitting	24 (88.9%)	168 (75.3%)	0.5
Secondary Progressive	2 (7.4%)	41 (18.4%)	
Primary Progressive	1 (3.7%)	13 (5.8%)	
Progressive Relapsing	0 (0%)	1 (0.4%)	
Most Recent DSS score			
Mean (SD)	3.11 (1.7)	3.57 (2.3)	0.2
Median [Min, Max]	3.0 [0, 7.0]	3.00 [0, 9.0]	
Post Onset Serum Sample Collection (years*)			

Mean (SD)	1.3 (0.5)	1.2 (0.4)	0.5
Median [Min, Max]	1.0 [1.0, 2.0]	1.00 [1.0, 2.0]	
*Time in years from first symptom onset to serum collection			